Fusion protein of chemoattracting small peptide and dual specific antibodies

A bispecific antibody and fusion protein technology, applied in the direction of anti-animal/human immunoglobulin, hybrid immunoglobulin, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve the problem of effector cells Problems such as limited quantity, difficulty in getting the most out of the role, etc., to achieve the effect of great application prospects

Inactive Publication Date: 2007-05-09
BEIJING ABT GENETIC ENG TECH
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the number of effector cells enriched in the tumor site is limited after all, making it difficult to maximize this effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein of chemoattracting small peptide and dual specific antibodies
  • Fusion protein of chemoattracting small peptide and dual specific antibodies
  • Fusion protein of chemoattracting small peptide and dual specific antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0042] In the context of the present invention, the terms used generally have the meanings commonly understood by those of ordinary skill in the art unless otherwise specified.

[0043] The fusion protein of the N-terminal octadecapeptide of the chemokine SLC and the anti-ovarian cancer × anti-CD3 bispecific antibody constructed in the present invention is constructed by genetic engineering and recombination, that is, it has the ability to attract T lymphocytes and dendritic cells It also has the function of activating T lymphocytes to kill tumors. Specifically, the fusion protein of the N-terminal octadecapeptide of the chemokine SLC and the bispecific antibody for ovarian cancer described in the present invention is the N-terminal octadecapeptide (GGGGS) of the CC family chemokine SLC with chemotactic ability 2 A molecule formed by linking peptides and anti-ovarian cancer × anti-CD3 bispecific antibodies in series. The present invention selects the N-terminal octadecapeptid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates to a fusion protein of chenotactic peptide and bispecific antibody against ovarian carcinoma and CD3 molecules. The fusion protein is constructed by sequentially connecting N-terminated 18-peptides of secondary lymphoid tissue chemokine, (GGGGS)2 linking peptide, and the bispecific antibody against ovarian carcinoma and CD3 molecules. C-myc label and His6 label are connected at the C-terminal. This invention also relates to the method for constructing, expressing and purifying the fusion protein, its coding sequence, its relevant expression vector, and the host cells containing the expression vector.

Description

technical field [0001] The present invention relates to the field of genetically engineered antibodies, and more specifically, relates to the combination of an N-terminal octadecapeptide of a chemokine SLC (Secondary lymphoid tissue chemokine) and an anti-ovarian cancer × anti-CD3 bispecific antibody The fusion protein; the method for constructing, expressing and purifying the fusion protein; the vector containing the fusion protein and Escherichia coli host bacteria. Background technique [0002] With the development of antibody engineering, immunotherapy is another important method for treating tumors after surgery, radiotherapy, and chemotherapy. The ideal treatment plan should be aimed at the specific and efficient killing of tumor cells, that is, bispecific antibodies that can bind to target tumor cells and highly cytotoxic effector cells are ideal candidates for this plan. On the one hand, it targets tumors to achieve specific combination with target tumor cells; on t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/46C07K7/00C07K16/30C07K1/14C07H21/00C12N5/10
Inventor 黄华樑宋景震王祥斌春雷朴锦华张众林晴
Owner BEIJING ABT GENETIC ENG TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap